Mirum Pharmaceuticals (MIRM) Ratios
Mirum Pharmaceuticals Ratios
MX:MIRM's free cash flow for Q2 2026 was $-273.70M. For the 2026 fiscal year, MX:MIRM's free cash flow was decreased by $-687.00K and operating cash flow was $-273.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.67 | 3.10 | 4.45 | 2.94 | 3.91 |
| Quick Ratio | 2.55 | 2.93 | 4.19 | 2.85 | 3.88 |
| Cash Ratio | 1.44 | 1.76 | 3.29 | 0.43 | 0.74 |
| Solvency Ratio | 0.00 | -0.14 | -0.38 | -0.63 | -0.48 |
| Operating Cash Flow Ratio | 0.27 | 0.08 | -0.81 | -1.86 | -3.12 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 21.56M | $ -52.33M | $ -10.41M | $ -20.64M | $ -7.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.38 | 0.47 | 0.48 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 1.02 | 1.41 | 1.24 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.50 | 0.58 | 0.55 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.50 | 0.58 | 0.55 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.68 | 2.97 | 2.60 | 2.48 | 2.45 |
| Debt Service Coverage Ratio | 1.06 | -3.49 | -9.10 | -7.29 | -3.72 |
| Interest Coverage Ratio | -1.54 | -6.12 | -7.23 | -8.21 | -9.86 |
| Debt to Market Cap | 0.08 | 0.16 | 0.25 | 0.00 | 0.00 |
| Interest Debt Per Share | 6.65 | 6.99 | 7.91 | 0.54 | 0.67 |
| Net Debt to EBITDA | 1.32 | -1.95 | -0.16 | 0.21 | 0.44 |
| Profitability Margins | |||||
| Gross Profit Margin | 80.71% | 75.77% | 74.76% | 83.94% | 90.06% |
| EBIT Margin | -1.35% | -21.55% | -79.04% | -163.62% | -346.75% |
| EBITDA Margin | 3.30% | -14.54% | -73.23% | -159.42% | -341.66% |
| Operating Profit Margin | -4.25% | -26.00% | -58.57% | -170.28% | -906.12% |
| Pretax Profit Margin | -4.11% | -25.80% | -87.15% | -184.36% | -438.66% |
| Net Profit Margin | -4.48% | -26.10% | -87.68% | -176.05% | -438.85% |
| Continuous Operations Profit Margin | -4.48% | -26.10% | -87.68% | -176.05% | -438.85% |
| Net Income Per EBT | 109.04% | 101.19% | 100.61% | 95.49% | 100.04% |
| EBT Per EBIT | 96.80% | 99.21% | 148.80% | 108.27% | 48.41% |
| Return on Assets (ROA) | -2.77% | -13.11% | -25.27% | -38.44% | -28.50% |
| Return on Equity (ROE) | -7.42% | -38.97% | -65.72% | -95.51% | -69.87% |
| Return on Capital Employed (ROCE) | -3.47% | -16.10% | -19.51% | -45.53% | -68.80% |
| Return on Invested Capital (ROIC) | -3.46% | -16.05% | -19.47% | -43.34% | -68.61% |
| Return on Tangible Assets | -4.02% | -20.89% | -41.51% | -46.15% | -30.44% |
| Earnings Yield | -0.59% | -4.48% | -13.54% | -20.56% | -17.37% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.23 | 4.30 | 2.74 | 3.21 | 5.86 |
| Payables Turnover | 10.46 | 5.59 | 6.34 | 1.42 | 0.21 |
| Inventory Turnover | 4.04 | 3.64 | 2.11 | 2.22 | 1.26 |
| Fixed Asset Turnover | 49.17 | 34.33 | 93.66 | 32.86 | 7.51 |
| Asset Turnover | 0.62 | 0.50 | 0.29 | 0.22 | 0.06 |
| Working Capital Turnover Ratio | 1.71 | 1.19 | 0.88 | 0.62 | 0.11 |
| Cash Conversion Cycle | 141.77 | 119.62 | 248.70 | 21.47 | -1405.56 |
| Days of Sales Outstanding | 86.35 | 84.82 | 133.11 | 113.65 | 62.31 |
| Days of Inventory Outstanding | 90.31 | 100.16 | 173.13 | 164.15 | 290.20 |
| Days of Payables Outstanding | 34.89 | 65.35 | 57.54 | 256.33 | 1758.06 |
| Operating Cycle | 176.66 | 184.98 | 306.24 | 277.80 | 352.51 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.11 | 0.22 | -1.74 | -3.55 | -4.38 |
| Free Cash Flow Per Share | 1.09 | 0.20 | -2.23 | -3.56 | -5.01 |
| Dividend Paid and CapEx Coverage Ratio | 58.52 | 10.40 | -3.53 | -432.14 | -6.98 |
| Capital Expenditure Coverage Ratio | 58.52 | 10.40 | -3.53 | -432.14 | -6.98 |
| Operating Cash Flow Coverage Ratio | 0.17 | 0.03 | -0.23 | -54.91 | -50.79 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.03 | -0.38 | -1.56 | -6.94 |
| Free Cash Flow Yield | 1.38% | 0.47% | -7.54% | -18.25% | -31.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -168.06 | -22.35 | -7.39 | -4.86 | -5.76 |
| Price-to-Sales (P/S) Ratio | 7.61 | 5.83 | 6.48 | 8.56 | 25.27 |
| Price-to-Book (P/B) Ratio | 12.60 | 8.71 | 4.85 | 4.65 | 4.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 72.26 | 210.57 | -13.26 | -5.48 | -3.19 |
| Price-to-Operating Cash Flow Ratio | 71.03 | 190.32 | -17.01 | -5.49 | -3.64 |
| Price-to-Earnings Growth (PEG) Ratio | 2.25 | 0.42 | 29.62 | -0.11 | 0.18 |
| Enterprise Value Multiple | 231.78 | -42.07 | -9.00 | -5.16 | -6.96 |
| Enterprise Value | 3.99B | 2.06B | 1.23B | 634.05M | 454.91M |
| EV to EBITDA | 231.78 | -42.07 | -9.00 | -5.16 | -6.96 |
| EV to Sales | 7.65 | 6.12 | 6.59 | 8.23 | 23.77 |
| EV to Free Cash Flow | 72.68 | 220.78 | -13.49 | -5.27 | -3.00 |
| EV to Operating Cash Flow | 71.43 | 199.55 | -17.32 | -5.28 | -3.43 |
| Tangible Book Value Per Share | 1.07 | -0.51 | -0.10 | 2.46 | 3.35 |
| Shareholders’ Equity Per Share | 6.27 | 4.75 | 6.08 | 4.20 | 3.96 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.09 | -0.01 | -0.01 | 0.05 | -0.00 |
| Revenue Per Share | 10.39 | 7.09 | 4.56 | 2.28 | 0.63 |
| Net Income Per Share | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 |
| Tax Burden | 1.09 | 1.01 | 1.01 | 0.95 | 1.00 |
| Interest Burden | 3.04 | 1.20 | 1.10 | 1.13 | 1.27 |
| Research & Development to Revenue | 0.36 | 0.42 | 0.55 | 1.39 | 6.87 |
| SG&A to Revenue | 0.49 | 0.60 | 0.75 | 0.00 | 2.61 |
| Stock-Based Compensation to Revenue | 0.14 | 0.14 | 0.19 | 0.35 | 1.21 |
| Income Quality | -2.39 | -0.12 | 0.43 | 0.89 | 1.58 |
Currency in USD
